CLAMOX FILM-COATED TABLETS 1G [SIN16749P]
Active ingredients: AMOXICILLIN TRIHYDRATE EQV AMOXICILLIN | POTASSIUM CLAVULANATE EQV CLAVULANIC ACID
Last updated on 9 October 2026
Product Info
CLAMOX FILM-COATED TABLETS 1G
[SIN16749P]
Product information
Active Ingredient and Strength | AMOXICILLIN TRIHYDRATE EQV AMOXICILLIN - 875 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | MICRO LABS LIMITED - INDIA |
Registration Number | SIN16749P |
Licence Holder | GOLDPLUS UNIVERSAL PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J01CR02 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
INDICATIONS:
Amoxicillin/clavulanic acid is an antibiotic agent with a notably broad spectrum of activity against the commonly occurring bacterial pathogens in general practice and hospital. The beta-lactamase inhibitory action of clavulanate extends the spectrum of amoxicillin to embrace a wider range of organisms, including many resistant to other beta-lactam antibiotics.
Amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.
Amoxicillin/clavulanic acid oral presentations for twice daily dosing, are indicated for short-term treatment of bacterial infections at the following sites:
Upper respiratory tract infections (including ENT) e.g. tonsillitis, sinusitis, otitis media.
Lower respiratory tract infections e.g. acute exacerbation of chronic bronchitis, lobar and bronchopneumonia.
Genito-urinary tract infections e.g. cystitis, urethritis, pyelonephritis.
Skin and soft tissue infections e.g. boils, abscesses, cellulitis, wound infections.
Bone and joint infections e.g. osteomyelitis.
Dental infections e.g. dentoalveolar abscess, pericoronitis, acute periodontitis.
Other infections e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis.
Susceptibility to amoxicillin/clavulanic acid will vary with geography and time (see Pharmacological Properties, Pharmacodynamics for further information – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.
Dosing
RECOMMENDED DOSAGE:
Dosage depends on the age and renal function of the patient and the severity of the infection.
To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of amoxicillin/clavulanic acid is optimised when taken at the start of a meal.
Treatment should not be extended beyond 14 days without review.
Therapy can be started parenterally and continued with an oral preparation.
Amoxicillin/clavulanic acid tablets are not recommended in children of 12 years and under.
Adults and Children over 12 years
The usual recommended daily dosage is:
Renal Impairment
No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 mL/min. The amoxicillin/clavulanic acid 1g tablet should only be used in patients with a creatinine clearance (CrCl) rate of more than 30 mL/min.
Hepatic Impairment
Dose with caution; monitor hepatic function at regular intervals.
Contraindications
CONTRAINDICATIONS:
Amoxicillin/clavulanic acid is contraindicated in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins.
Amoxicillin/clavulanic acid is contraindicated in patients with a previous history of amoxicillin/clavulanic acid -associated jaundice/hepatic dysfunction.